Health Care • Biotechnology: Pharmaceutical Preparations
$290.79 ▲ +4.80
(+1.68%)
MKT CAP: $513.86B • VOL: 4.33M
52W L $191 52W H $299
ABBV // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $61.16B | $56.33B | $54.32B |
| YoY Revenue Growth % | +8.6% | +3.7% | — |
| Gross Profit | $42.96B | $39.43B | $23.90B |
| Gross Margin % | 70.2% | 70.0% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $15.07B | $9.14B | $12.76B |
| Operating Margin % | 24.6% | 16.2% | 23.5% |
| Net Income (GAAP) | $4.23B | $4.28B | $4.86B |
| EBITDA (Normalized) | $16.05B | $9.92B | $14.71B |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $19.03B | $18.81B | $22.84B |
| Capital Expenditures (CapEx) | $1.21B | $974.0M | $2.44B |
| Free Cash Flow (FCF) | $17.82B | $17.83B | $20.39B |
| FCF Margin % | 29.1% | 31.7% | 37.5% |
| Return on Invested Capital (ROIC %) | 52.1% | 24.5% | 5.9% |
| Cash & Short-Term Equivalents | $5.23B | $5.52B | $31.09B |
| Total Debt (Short + Long Term) | $31.35B | $31.63B | $66.13B |
| Total Stockholders' Equity | -$3.27B | $3.33B | $135.66B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ABBV.